Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Unless you’ve been living under a rock, you know that weight-loss drugs are the talk of the town. GLP-1 drugs, in particular, ...

Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall ...

Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Tiny doses of the weight-loss drug can sidestep its unpleasant side effects, say influencers. But is customising the dose a ...

PERSPECTIVES: The resurgence of Y2K skin-baring fashion trends coincides with the rise of prescription weight loss drugs like ...

Attempts to restrict pharmaceutical advertisements have failed many times over the years, often on First Amendment grounds.

Lilly’s Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive ...